9 December 2023
Kirkland Advises AbbVie on $8.7 Billion Acquisition of Cerevel Therapeutics
Advising firms
Deal team
15 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Eric Schiele | Kirkland & Ellis | Partner | corporate | Not stated |
| Carlo Zenkner | Kirkland & Ellis | Partner | corporate | Not stated |
| Jimin He | Kirkland & Ellis | Partner | corporate | Not stated |
| Rachel Sheridan | Kirkland & Ellis | Partner | capital markets | Not stated |
| Zoey Hitzert | Kirkland & Ellis | Partner | capital markets | Not stated |
| Yuli Wang | Kirkland & Ellis | Partner | debt finance | Not stated |
| Scott Price | Kirkland & Ellis | Partner | executive compensation | Not stated |
| Jack Stratton | Kirkland & Ellis | Partner | executive compensation | Not stated |
| Risa Salins | Kirkland & Ellis | Partner | employment & labor | Not stated |
| Maureen O'Brien | Kirkland & Ellis | Partner | employee benefits | Not stated |
| Dennis Williams | Kirkland & Ellis | Partner | healthcare regulatory | Not stated |
| Kate Hardey | Kirkland & Ellis | Partner | healthcare regulatory | Not stated |
| Adam Petravicius | Kirkland & Ellis | Partner | technology & IP transaction | Not stated |
| Matt Darch | Kirkland & Ellis | Partner | technology & IP transaction | Not stated |
| Luci Hague | Kirkland & Ellis | Partner | international trade & national security | Not stated |
Stated terms
- Stated value
- USD 8.70bn ($8.7 billion)
- What the figure measures
- Total transaction value
- Client
- AbbVie Inc.Buy-side
- Counterparties
- Cerevel Therapeutics (Sell-side)